Cost analysis of diagnostic testing for coronary artery disease in women with stable chest pain

Leslee J. Shaw, Gary V. Heller, Mark I. Travin, Michael Lauer, Thomas Marwick, Rory Hachamovitch, Daniel S. Berman, D. Douglas Miller

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background. Seven clinical sites compiled data from 4638 women who were referred directly to coronary angiography (catheterization-first strategy; n = 3375) or who underwent stress myocardial perfusion imaging (MPI) first (n = 1263) followed by coronary angiography if at least one reversible myocardial perfusion abnormality was detected. The study examines the cost minimization potential of these available invasive and noninvasive diagnostic strategies in women with chest pain. Methods and Results. Women in both groups were subclassified by the core laboratory as being at low (< 0.15), intermediate (0.15 to 0.60), or high (> 0.60) pretest likelihood for coronary artery disease (CAD). Among the catheterization-first patients, at least one coronary stenosis > 70% was present in 13% of low likelihood patients, 29% of intermediate likelihood patients, and 52% of patients with high CAD likelihood. Perfusion abnormality rates in the MPI-first group were 23% in low likelihood patients, 27% in intermediate likelihood patients, and 34% in high CAD likelihood patients. Of the MPI-first subset, 50%, 55%, and 76%, respectively, underwent catheterization in at least one coronary stenosis > 70%. Cardiac death rates ranged from 0.5% to 2.2% in patients with CAD and did not differ from the 2 testing strategies (P = not significant). The composite cost per patient of diagnostic testing plus follow-up medical care over a period of 2.5 ± 1.5 years (calculated for both strategies from inflation-corrected Medicare charges, adjusted for institutional cost-charge ratios) ranged from $2490 for patients with low likelihood to $3687 for patients with high likelihood with the catheterization-first strategy and from $1587 to $2585 for patients undergoing MPI first (P < .01 between risk subsets and strategies). Conclusions. In women referred for diagnostic evaluation of stable chest pain, MPI followed by selective coronary angiography in patients with at least 1 perfusion abnormality minimizes the near-term composite cost per patient compared with a direct catheterization-first strategy, regardless of pretest CAD likelihood.

Original languageEnglish (US)
Pages (from-to)559-569
Number of pages11
JournalJournal of Nuclear Cardiology
Volume6
Issue number6
StatePublished - Nov 1999

Fingerprint

Chest Pain
Coronary Artery Disease
Costs and Cost Analysis
Myocardial Perfusion Imaging
Catheterization
Coronary Angiography
Perfusion
Coronary Stenosis
Aftercare
Economic Inflation
Medicare

Keywords

  • Coronary artery disease
  • Cost
  • Diagnostic testing
  • Myocardial imaging
  • Patient outcomes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Shaw, L. J., Heller, G. V., Travin, M. I., Lauer, M., Marwick, T., Hachamovitch, R., ... Miller, D. D. (1999). Cost analysis of diagnostic testing for coronary artery disease in women with stable chest pain. Journal of Nuclear Cardiology, 6(6), 559-569.

Cost analysis of diagnostic testing for coronary artery disease in women with stable chest pain. / Shaw, Leslee J.; Heller, Gary V.; Travin, Mark I.; Lauer, Michael; Marwick, Thomas; Hachamovitch, Rory; Berman, Daniel S.; Miller, D. Douglas.

In: Journal of Nuclear Cardiology, Vol. 6, No. 6, 11.1999, p. 559-569.

Research output: Contribution to journalArticle

Shaw, LJ, Heller, GV, Travin, MI, Lauer, M, Marwick, T, Hachamovitch, R, Berman, DS & Miller, DD 1999, 'Cost analysis of diagnostic testing for coronary artery disease in women with stable chest pain', Journal of Nuclear Cardiology, vol. 6, no. 6, pp. 559-569.
Shaw, Leslee J. ; Heller, Gary V. ; Travin, Mark I. ; Lauer, Michael ; Marwick, Thomas ; Hachamovitch, Rory ; Berman, Daniel S. ; Miller, D. Douglas. / Cost analysis of diagnostic testing for coronary artery disease in women with stable chest pain. In: Journal of Nuclear Cardiology. 1999 ; Vol. 6, No. 6. pp. 559-569.
@article{a458f9c9d4af426f993e0d6db8a0825e,
title = "Cost analysis of diagnostic testing for coronary artery disease in women with stable chest pain",
abstract = "Background. Seven clinical sites compiled data from 4638 women who were referred directly to coronary angiography (catheterization-first strategy; n = 3375) or who underwent stress myocardial perfusion imaging (MPI) first (n = 1263) followed by coronary angiography if at least one reversible myocardial perfusion abnormality was detected. The study examines the cost minimization potential of these available invasive and noninvasive diagnostic strategies in women with chest pain. Methods and Results. Women in both groups were subclassified by the core laboratory as being at low (< 0.15), intermediate (0.15 to 0.60), or high (> 0.60) pretest likelihood for coronary artery disease (CAD). Among the catheterization-first patients, at least one coronary stenosis > 70{\%} was present in 13{\%} of low likelihood patients, 29{\%} of intermediate likelihood patients, and 52{\%} of patients with high CAD likelihood. Perfusion abnormality rates in the MPI-first group were 23{\%} in low likelihood patients, 27{\%} in intermediate likelihood patients, and 34{\%} in high CAD likelihood patients. Of the MPI-first subset, 50{\%}, 55{\%}, and 76{\%}, respectively, underwent catheterization in at least one coronary stenosis > 70{\%}. Cardiac death rates ranged from 0.5{\%} to 2.2{\%} in patients with CAD and did not differ from the 2 testing strategies (P = not significant). The composite cost per patient of diagnostic testing plus follow-up medical care over a period of 2.5 ± 1.5 years (calculated for both strategies from inflation-corrected Medicare charges, adjusted for institutional cost-charge ratios) ranged from $2490 for patients with low likelihood to $3687 for patients with high likelihood with the catheterization-first strategy and from $1587 to $2585 for patients undergoing MPI first (P < .01 between risk subsets and strategies). Conclusions. In women referred for diagnostic evaluation of stable chest pain, MPI followed by selective coronary angiography in patients with at least 1 perfusion abnormality minimizes the near-term composite cost per patient compared with a direct catheterization-first strategy, regardless of pretest CAD likelihood.",
keywords = "Coronary artery disease, Cost, Diagnostic testing, Myocardial imaging, Patient outcomes",
author = "Shaw, {Leslee J.} and Heller, {Gary V.} and Travin, {Mark I.} and Michael Lauer and Thomas Marwick and Rory Hachamovitch and Berman, {Daniel S.} and Miller, {D. Douglas}",
year = "1999",
month = "11",
language = "English (US)",
volume = "6",
pages = "559--569",
journal = "Journal of Nuclear Cardiology",
issn = "1071-3581",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Cost analysis of diagnostic testing for coronary artery disease in women with stable chest pain

AU - Shaw, Leslee J.

AU - Heller, Gary V.

AU - Travin, Mark I.

AU - Lauer, Michael

AU - Marwick, Thomas

AU - Hachamovitch, Rory

AU - Berman, Daniel S.

AU - Miller, D. Douglas

PY - 1999/11

Y1 - 1999/11

N2 - Background. Seven clinical sites compiled data from 4638 women who were referred directly to coronary angiography (catheterization-first strategy; n = 3375) or who underwent stress myocardial perfusion imaging (MPI) first (n = 1263) followed by coronary angiography if at least one reversible myocardial perfusion abnormality was detected. The study examines the cost minimization potential of these available invasive and noninvasive diagnostic strategies in women with chest pain. Methods and Results. Women in both groups were subclassified by the core laboratory as being at low (< 0.15), intermediate (0.15 to 0.60), or high (> 0.60) pretest likelihood for coronary artery disease (CAD). Among the catheterization-first patients, at least one coronary stenosis > 70% was present in 13% of low likelihood patients, 29% of intermediate likelihood patients, and 52% of patients with high CAD likelihood. Perfusion abnormality rates in the MPI-first group were 23% in low likelihood patients, 27% in intermediate likelihood patients, and 34% in high CAD likelihood patients. Of the MPI-first subset, 50%, 55%, and 76%, respectively, underwent catheterization in at least one coronary stenosis > 70%. Cardiac death rates ranged from 0.5% to 2.2% in patients with CAD and did not differ from the 2 testing strategies (P = not significant). The composite cost per patient of diagnostic testing plus follow-up medical care over a period of 2.5 ± 1.5 years (calculated for both strategies from inflation-corrected Medicare charges, adjusted for institutional cost-charge ratios) ranged from $2490 for patients with low likelihood to $3687 for patients with high likelihood with the catheterization-first strategy and from $1587 to $2585 for patients undergoing MPI first (P < .01 between risk subsets and strategies). Conclusions. In women referred for diagnostic evaluation of stable chest pain, MPI followed by selective coronary angiography in patients with at least 1 perfusion abnormality minimizes the near-term composite cost per patient compared with a direct catheterization-first strategy, regardless of pretest CAD likelihood.

AB - Background. Seven clinical sites compiled data from 4638 women who were referred directly to coronary angiography (catheterization-first strategy; n = 3375) or who underwent stress myocardial perfusion imaging (MPI) first (n = 1263) followed by coronary angiography if at least one reversible myocardial perfusion abnormality was detected. The study examines the cost minimization potential of these available invasive and noninvasive diagnostic strategies in women with chest pain. Methods and Results. Women in both groups were subclassified by the core laboratory as being at low (< 0.15), intermediate (0.15 to 0.60), or high (> 0.60) pretest likelihood for coronary artery disease (CAD). Among the catheterization-first patients, at least one coronary stenosis > 70% was present in 13% of low likelihood patients, 29% of intermediate likelihood patients, and 52% of patients with high CAD likelihood. Perfusion abnormality rates in the MPI-first group were 23% in low likelihood patients, 27% in intermediate likelihood patients, and 34% in high CAD likelihood patients. Of the MPI-first subset, 50%, 55%, and 76%, respectively, underwent catheterization in at least one coronary stenosis > 70%. Cardiac death rates ranged from 0.5% to 2.2% in patients with CAD and did not differ from the 2 testing strategies (P = not significant). The composite cost per patient of diagnostic testing plus follow-up medical care over a period of 2.5 ± 1.5 years (calculated for both strategies from inflation-corrected Medicare charges, adjusted for institutional cost-charge ratios) ranged from $2490 for patients with low likelihood to $3687 for patients with high likelihood with the catheterization-first strategy and from $1587 to $2585 for patients undergoing MPI first (P < .01 between risk subsets and strategies). Conclusions. In women referred for diagnostic evaluation of stable chest pain, MPI followed by selective coronary angiography in patients with at least 1 perfusion abnormality minimizes the near-term composite cost per patient compared with a direct catheterization-first strategy, regardless of pretest CAD likelihood.

KW - Coronary artery disease

KW - Cost

KW - Diagnostic testing

KW - Myocardial imaging

KW - Patient outcomes

UR - http://www.scopus.com/inward/record.url?scp=0033402750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033402750&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 559

EP - 569

JO - Journal of Nuclear Cardiology

JF - Journal of Nuclear Cardiology

SN - 1071-3581

IS - 6

ER -